UroVysion: Difference between revisions
CSV import |
CSV import |
||
| Line 25: | Line 25: | ||
{{stub}} | {{stub}} | ||
__NOINDEX__ | __NOINDEX__ | ||
{{No image}} | |||
Revision as of 18:59, 10 February 2025
UroVysion is a fluorescence in situ hybridization (FISH) test that is used to detect chromosome abnormalities in the urine of patients who have bladder cancer or are at risk for bladder cancer. The test is performed by Abbott Laboratories and was approved by the FDA in 2001.
Overview
The UroVysion test uses DNA probes to target the chromosomes that are most often found to be abnormal in bladder cancer cells. These chromosomes are numbers 3, 7, 17, and the 9p21 gene. The test can detect these abnormalities in cells that are shed into the urine from the lining of the bladder.
Procedure
The UroVysion test is performed on a urine sample. The sample is treated with the DNA probes, which bind to their target chromosomes. The probes are labeled with different fluorescent colors, so when they bind to the chromosomes, they cause them to glow under a fluorescent microscope. This allows the laboratory technician to see if there are any abnormalities in the chromosomes.
Interpretation
The results of the UroVysion test can help doctors to diagnose bladder cancer, monitor patients who have had bladder cancer, and assess the risk of bladder cancer in patients with hematuria (blood in the urine) or other symptoms of bladder cancer. However, the test is not 100% accurate and should be used in conjunction with other diagnostic tests and procedures.
Limitations
While the UroVysion test can be a useful tool in the diagnosis and monitoring of bladder cancer, it does have some limitations. For example, it may not detect all cases of bladder cancer, especially in the early stages. In addition, it may produce false-positive results, indicating that cancer is present when it is not. Therefore, it is important to use the UroVysion test as part of a comprehensive diagnostic approach.
